Christoph Stephan

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Travel-acquired dengue infection: clinical spectrum and diagnostic aspects
    C Stephan
    Clinic for Internal Medicine, Dept of Infectious Disease, Frankfurt am Main, Germany
    Infection 30:225-8. 2002
  2. ncbi Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
    Christoph Stephan
    Division of Infectious Disease, and Institute of Clinical Pharmacology, Pharma Center, JW Goethe University Hospital, Frankfurt, Germany
    AIDS 18:503-8. 2004
  3. ncbi Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient
    Christoph Stephan
    AIDS 18:1613-4. 2004
  4. ncbi Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus
    Christoph Stephan
    HIV Research and Treatment Unit at Center for Internal Medicine, Johann Wolfgang Goethe University Hospital Frankfurt, Germany
    J Antimicrob Chemother 56:1087-93. 2005
  5. ncbi The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
    Schlomo Staszewski
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 58:1024-30. 2006
  6. ncbi [Leptospirosis after a staff outing]
    C Stephan
    Schwerpunkt Infektiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Dtsch Med Wochenschr 125:623-7. 2000
  7. ncbi Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
    C Stephan
    Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Eur J Med Res 15:369-76. 2010
  8. ncbi Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R
    C Stephan
    HIVCENTER, Johann Wolfgang Goethe University Hospital, Department of Internal Medicine II, Theodor Stern Kai 7, Frankfurt, Germany
    J Infect 61:346-50. 2010
  9. ncbi Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country
    Christoph Stephan
    HIVCENTER at Medical Department II, Hospital of Johann Wolfgang Goethe University, Frankfurt, Germany
    AIDS 22:2471-9. 2008
  10. ncbi [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]
    Christoph Stephan
    Schwerpunkt Therapie der HIV Infektion, Zentrum der Inneren Medizin, Klinik 2 Hämatologie Onkologie, Rheumatologie und Infektiologie, Klinikum der Johann Wolfgang Goethe Universität Frankfurt Main, Frankfurt Main
    Med Klin (Munich) 103:69-74. 2008

Detail Information

Publications26

  1. ncbi Travel-acquired dengue infection: clinical spectrum and diagnostic aspects
    C Stephan
    Clinic for Internal Medicine, Dept of Infectious Disease, Frankfurt am Main, Germany
    Infection 30:225-8. 2002
    ..Only few studies focus on clinical manifestations and serological findings in primarily nonimmune individuals...
  2. ncbi Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
    Christoph Stephan
    Division of Infectious Disease, and Institute of Clinical Pharmacology, Pharma Center, JW Goethe University Hospital, Frankfurt, Germany
    AIDS 18:503-8. 2004
    ..To assess the pharmacokinetic interaction of saquinavir and lopinavir/ritonavir...
  3. ncbi Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient
    Christoph Stephan
    AIDS 18:1613-4. 2004
  4. ncbi Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus
    Christoph Stephan
    HIV Research and Treatment Unit at Center for Internal Medicine, Johann Wolfgang Goethe University Hospital Frankfurt, Germany
    J Antimicrob Chemother 56:1087-93. 2005
    ..We studied the impact of tenofovir disoproxil fumarate, given as an antiretroviral medication, on patients with chronic hepatitis B virus (HBV) co-infection...
  5. ncbi The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
    Schlomo Staszewski
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    J Antimicrob Chemother 58:1024-30. 2006
    ..This regimen may not be suitable for patients with very low baseline CD4 cell counts, very broad antiretroviral therapy experience or extensive PI-resistance mutations...
  6. ncbi [Leptospirosis after a staff outing]
    C Stephan
    Schwerpunkt Infektiologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Dtsch Med Wochenschr 125:623-7. 2000
    ..About 18 days before they had been together on a boat rafting tour when the boat capsized when they had fallen into a river in high flood...
  7. ncbi Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
    C Stephan
    Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Eur J Med Res 15:369-76. 2010
    ..This analysis presents data from the German subgroup of protease inhibitor (PI)-pretreated, but SQV-naive patients...
  8. ncbi Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R
    C Stephan
    HIVCENTER, Johann Wolfgang Goethe University Hospital, Department of Internal Medicine II, Theodor Stern Kai 7, Frankfurt, Germany
    J Infect 61:346-50. 2010
    ..The reverse transcriptase (RT)-mutation K65R limits further therapeutic options and has been selected by unfavorable RT-combinations, e.g. tenofovir in combination with abacavir and/or didanosine...
  9. ncbi Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country
    Christoph Stephan
    HIVCENTER at Medical Department II, Hospital of Johann Wolfgang Goethe University, Frankfurt, Germany
    AIDS 22:2471-9. 2008
    ..To evaluate the interferon-gamma-releasing assays QuantiFERON-tuberculosis (TB) Gold and T-SPOT.TB in addition to tuberculin skin test (TST) for diagnosis of latent tuberculosis infection in HIV patients...
  10. ncbi [No obvious difference in Streptococcus pneumoniae antibiotic resistance profiles--isolates from HIV-positive and HIV-negative patients]
    Christoph Stephan
    Schwerpunkt Therapie der HIV Infektion, Zentrum der Inneren Medizin, Klinik 2 Hämatologie Onkologie, Rheumatologie und Infektiologie, Klinikum der Johann Wolfgang Goethe Universität Frankfurt Main, Frankfurt Main
    Med Klin (Munich) 103:69-74. 2008
    ..The purpose of this case-control study was to determine the susceptibility patterns of pneumococci from adult patients in relation to their HIV status and to compare both patient groups...
  11. ncbi Dose reduction effective in alleviating symptoms of saquinavir toxicity
    C Stephan
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Department of Internal Medicine II, Frankfurt, Germany
    Int J STD AIDS 18:81-4. 2007
    ..Although delayed autoinduction is not well established as a reason for adverse events in saquinavir therapy, this observation may be confirmed in the near future by increased use...
  12. ncbi Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Christoph Stephan
    Johann Wolfgang Goethe University Hospital, HIV Treatment and Clinical Research Unit, Medical Department II, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Curr HIV Res 7:320-6. 2009
    ..We investigated the virologic and immunologic responses to a mono-class, nucleoside/nucleotide reverse transcriptase inhibitor - combination therapy consisting of tenofovir and zidovudine/lamivudine/abacavir in therapy experienced patients...
  13. ncbi Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy
    Nils von Hentig
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Antivir Ther 13:1039-46. 2008
    ....
  14. ncbi Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
    Annette Haberl
    HIVCENTER, Medical Clinics II, J W Goethe University Hospital, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 66:375-81. 2010
    ..We performed a matched-pairs analysis on 24 patients (12 men/women) taking atazanavir/ritonavir 300/100 mg daily plus reverse transcriptase inhibitors, with (n = 12) or without (n = 12) methadone co-administration...
  15. ncbi Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Clinic of the Goethe University, Frankfurt, Germany
    Clin Infect Dis 52:122-7. 2011
    ..gov NCT01017172)...
  16. ncbi Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 52:2273-5. 2008
    ..Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised...
  17. ncbi Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Frankfurt, Germany
    AIDS 24:F31-5. 2010
    ..To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172)...
  18. ncbi Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis
    Markus Bickel
    HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    Scand J Infect Dis 37:520-2. 2005
    ..Plasma levels of efavirenz were 10 times the upper limit and remained elevated (at twice the upper limit) 4 weeks after cessation of therapy. Efavirenz resistance (K103N) developed and was probably due to 'functional' monotherapy...
  19. ncbi Experience with tenofovir disoproxil fumarate for antiretroviral therapy
    Christoph Stephan
    Hospital of the Johann Wolfgang Goethe University, Internal Medicine and Infectious Diseases, Medical HIV Treatment and Research Unit, Department of Internal Medicine II, Frankfurt, Germany
    Expert Opin Pharmacother 9:1197-209. 2008
    ..This article describes the efficacy and safety of tenofovir disoproxil fumarate from ongoing and recent clinical trials, and key aspects of its broad, clinical experience since its introduction...
  20. ncbi The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load
    M Bickel
    Department of Infectious Disease, HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    HIV Med 6:179-84. 2005
    ....
  21. ncbi Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes
    Martin Stürmer
    Johann Wolfgang Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
    Antimicrob Agents Chemother 55:5362-6. 2011
    ..Current algorithms appear suboptimal for interpretation of resistance to tipranavir in non-B subtypes; increased scores might reflect algorithm bias rather than "natural resistance."..
  22. ncbi Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients
    M Bickel
    HIVCENTER, JW Goethe University Hospital, Theodor Stern Kai 7, Frankfurt, Germany
    J Antimicrob Chemother 64:1260-4. 2009
    ..To investigate the feasibility and pharmacokinetics of a once-daily regimen of 2000 mg saquinavir mesylate boosted with 100 mg ritonavir...
  23. ncbi Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis
    M W Lorenz
    Johann Wolfgang Goethe University Hospital, Department of Neurology, Frankfurt am Main, Germany
    Atherosclerosis 196:720-6. 2008
    ..We investigated the relationship between HIV infection, antiretroviral medication and ultrasound evidence of early atherosclerosis in the context of vascular risk factors...
  24. ncbi Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects
    G Just-Nübling
    Dept of Infectiology, Medical Clinic III, J W Goethe University Hospital, Theodor Stern Kai 7, D 60590, Frankfurt am Main, Germany
    Infection 31:318-23. 2003
    ..Occasionally, primary cytomegalovirus (CMV) infection may give rise to more or less severe clinical illness in immunocompetent adults. We retrospectively analyzed cases of acute CMV infection in medical outpatients...
  25. ncbi A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophy
    M Bickel
    HIV Medical Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    HIV Med 8:413-9. 2007
    ..Although multiple methods have been proposed, there is no current gold standard for assessing HIV-1-associated lipodystrophy...
  26. ncbi Winterbottom's sign and hypertrophic cardiomyopathy
    Christoph Stephan
    Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Scand J Infect Dis 34:544-5. 2002
    ..He made a full recovery after intravenous administration of eflornithine, a drug that is no longer distributed for antiparasitic indications for pharmacoeconomic reasons...